Expect positive sentiment on pipeline depth and growth narrative, though near-term P&L impact is limited until NDA filing and potential approval. Key catalyst: NDA acceptance and FDA review timeline in H2 2026. Monitor Phase 3 data details and competitive landscape in Tourette syndrome.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 10 $33.58entry
- T+1 · 5mo ago +2.92%α +1.22% · $34.56
- T+5 · 5mo ago −2.00%α −5.43% · $32.91
- T+20 · 4mo ago −1.43%α −5.05% · $33.10
- T+60 · 2mo ago +9.01%α +2.43% · $36.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva closed its acquisition of Emalex Biosciences for $700M upfront plus up to $200M in milestones and sales-based royalties, adding ecopipam, a late-stage, first-in-class D1 antagonist for pediatric Tourette syndrome. NDA submission is expected in H2 2026, and Phase 3 data published in JAMA Neurology showed statistical significance on the primary endpoint.
Key Financial Metrics
Key Facts
- $700 million upfront consideration paid at closing
- Up to $200 million in additional commercial milestone payments plus net sales-based royalties
- Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations
- Phase 3 Tourette syndrome study met primary endpoint with statistical significance (p = 0.0084) and was published in JAMA Neurology
- NDA submission anticipated in second half of 2026
- Expands Teva's innovative pipeline in neuroscience with significant unmet need, supporting the Pivot to Growth strategy
Financial Impact
$700M upfront + up to $200M milestones + royalties; Teva market cap ~$40B, so ~2.25% of market cap at risk upfront with upside from commercial milestones
Risk Factors
- Regulatory risk: ecopipam may not gain FDA approval
- Commercial risk: Tourette syndrome market is niche (Orphan Drug designation indicates <200K patients)
- Integration and execution risk: Teva must successfully file NDA and launch a new neuroscience asset
- Additional $200M milestone payments and royalties could pressure near-term cash flow if sales disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309960 |
Track record
61 reports on TEVA
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers